Benjamin M. Beckermann

Most-cited papers

1. Sulforaphane targets pancreatic tumour-initiating cells by NF-κB-induced antiapoptotic signalling

   G. Kallifatidis, V. Rausch, B. Baumann, A. Apel +13 more

   2008Gut237 citations

   Semantic Scholar

   Save

2. Corticosteroids induce chemotherapy resistance in the majority of tumour cells from bone, brain, breast, cervix, melanoma and neuroblastoma.

   Cheng-Wen Zhang, Benjamin M. Beckermann, G. Kallifatidis, Zheng Liu +7 more

   2006International Journal of Oncology94 citations Open access

   Semantic Scholar

   Save

3. Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial

   M. Konopleva, C. Röllig, J. Cavenagh, D. Deeren +23 more

   2022Blood Advances78 citations Open access

   Semantic Scholar

   Save

4. MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia.

   P. Montesinos, Benjamin M. Beckermann, O. Catalani, J. Esteve +13 more

   2020Future Oncology78 citations Open access

   Semantic Scholar

   Save

5. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study.

   C. Négrier, J. Mahlangu, M. Lehle, P. Chowdary +14 more

   2023The Lancet Haematology70 citations Open access

   Semantic Scholar

   Save

6. Targeting of cancer stem cell marker EpCAM by bispecific antibody EpCAMxCD3 inhibits pancreatic carcinoma

   A. V. Salnikov, A. Groth, A. Apel, G. Kallifatidis +6 more

   2009Journal of Cellular and Molecular Medicine49 citations Open access

   Semantic Scholar

   Save

7. Emicizumab Prophylaxis in Persons with Mild or Moderate Hemophilia A: Results from the Interim Analysis of the HAVEN 6 Study

   C. Négrier, J. Mahlangu, M. Lehle, P. Chowdary +13 more

   2021Blood12 citations Open access

   Semantic Scholar

   Save

8. Emicizumab use in females with moderate or mild hemophilia A without factor VIII inhibitors who warrant prophylaxis

   Cédric Hermans, G. Ventriglia, Samya Obaji, Benjamin M. Beckermann +4 more

   2023Research and Practice in Thrombosis and Haemostasis5 citations Open access

   Semantic Scholar

   Save

9. Contribution of Idasanutlin Exposure to Safety, Pharmacodynamics and Clinical Response of Patients with Acute Myeloid Leukemia Treated with Idasanutlin + Cytarabine in Phase I and III Studies

   C. Jamois, Doreen Anders, Benjamin M. Beckermann, M. Genevray +5 more

   20204 citations

   Semantic Scholar

   Save

10. Patient-reported outcomes (PROs) from MARIANNE: A phase III study of trastuzumab emtansine (T-DM1) +/- pertuzumab (P) vs trastuzumab + taxane (HT) for HER2-positive advanced breast cancer.

    C. Barrios, D. Cella, Miguel Martín, W. Eiermann +10 more

    20161 citations

    Semantic Scholar

    Save